Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies

Demonstrates Greater Binding Affinity Than Previous Antibodies

Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: “HALB“) announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19.  Each of these new antibodies bind to different parts of the Spike protein antigen than the earlier antibodies.  It is believed that these new antibodies, used together in a cocktail with Halberd’s earlier designed antibodies could bind, attack, and neutralize the SARS-CoV-2 antigen, and many of its mutations, on several fronts.

Binding strength of the antibodies to the target antigen is a critically important characteristic for implementation of Halberd’s extracorporeal treatment process to eradicate the target disease antigen through exposure to radiofrequency waves or laser emissive energy.

William A. Hartman, Halberd’s Chairman, President & CEO, commented, “Halberd now has four antibodies specifically targeting the SARS-CoV-2 Spike Protein antigen. Each Halberd antibody displays different characteristics and capability of binding to different parts of the spike protein.  This provides Halberd with additional tools in fighting Covid-19 and many of its mutations.”

Hartman continued, “Together with our patented extracorporeal treatment process, we believe we have an effective method of treating viruses and bacterial infections which are resistant to conventional therapies.  Halberd’s strategy continues to follow our process road map consisting of:

1. Identifying a target antigen;
2. Creating patentable antibodies with high binding affinity against the target antigen;
3. Conjugating these antibodies with metallic nanoparticles (moieties) through a patent-pending process;
4. Applying Halberd’s patented extracorporeal process of eradicating the moiety-antigen complex in bodily fluids through the patent-pending process of exposing it to radiofrequency waves or laser emissive energy;
5. Conducting animal testing to establish the safety and efficacy of our revolutionary process for the eradication of diseases.

“We have successfully completed steps 1, 2, & 3. We are in the process of executing Step 4 for effectiveness against the SARS-Cov-2 spike protein and E. coli bacteria.  This will be followed by executing animal testing, for which the groundwork is already being laid.”

“After completion of the E. coli and spike protein experimentation, we will focus our technological advancements on other pathogens.”

Mr. Hartman concluded, “Our excitement aligns with the prospect of universal disease eradication through this unique and patented methodology which only Halberd can pursue. We are driven to restore hope to those with untreatable diseases and to make the term ‘untreatable diseases’ something of the past.”

To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
https://halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.